Progression of ocular melanoma metastasis to the liver: The 2012 Zimmerman lecture

JAMA Ophthalmology

Volumn 131, Issue 4, 2013, Pages 462-469

  Grossniklaus, Hans E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; AUTOPSY; CANCER GROWTH; CANCER MORTALITY; CANCER PATIENT; CANCER STAGING; CLINICAL ARTICLE; DISEASE SEVERITY; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER; LIVER METASTASIS; MITOSIS INDEX; MORPHOLOGY; PRIORITY JOURNAL; TISSUE SECTION; UVEA MELANOMA;

ADULT; BRACHYTHERAPY; DISEASE PROGRESSION; EYE ENUCLEATION; HUMANS; LIVER NEOPLASMS; MELANOMA; MITOTIC INDEX; NEOPLASM STAGING; NEOVASCULARIZATION, PATHOLOGIC; TUMOR MARKERS, BIOLOGICAL; UVEAL NEOPLASMS;

EID: 84876215338     PISSN: 21686165     EISSN: None     Source Type: Journal    
DOI: 10.1001/jamaophthalmol.2013.2547     Document Type: Article

References (29)

1. Singh AD, Shields CL, Shields JA. Prognostic factors in uveal melanoma. Melanoma Res. 2001;11(3):255-263.
2. Singh AD, Topham A. Incidence of uveal melanoma in the United States: 1973-1997. Ophthalmology. 2003;110(5):956-961.
3. Stang A, Jöckel KH. Trends in the incidence of ocular melanoma in the United States, 1974-1998. Cancer Causes Control. 2004;15(1):95-96, author reply 101-102.
4. Burr JM, Mitry E, Rachet B, Coleman MP. Survival from uveal melanoma in England and Wales 1986 to 2001. Ophthalmic Epidemiol. 2007;14(1):3-8.
5. Collaborative Ocular Melanoma Study Group. Assessment of metastatic disease status at death in 435 patients with large choroidal melanoma in the Collaborative Ocular Melanoma Study (COMS): COMS report no. 15. Arch Ophthalmol. 2001;119(5):670-676.
6. Bedikian AY. Metastatic uveal melanoma therapy: current options. Int Ophthal-mol Clin. 2006;46(1):151-166.
7. Augsburger JJ, Corrêa ZM, Shaikh AH. Effectiveness of treatments for meta-static uveal melanoma. Am J Ophthalmol. 2009;148(1):119-127.
8. Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420-425.
9. Singh AD, Rennie IG, Kivela T, Seregard S, Grossniklaus H. The Zimmerman-McLean-Foster hypothesis: 25 years later. Br J Ophthalmol. 2004;88(7):962-967.
10. Eskelin S, Pyrhönen S, Summanen P, Hahka-Kemppinen M, Kivelä T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443-1449.
11. Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology. 2001;108(5):829-831.
12. Borthwick NJ, Thombs J, Polak M, et al. The biology of micrometastases from uveal melanoma. J Clin Pathol. 2011;64(8):666-671.
13. Hendrix MJ, Seftor EA, Seftor RE, et al. Regulation of uveal melanoma intercon-verted phenotype by hepatocyte growth factor/scatter factor (HGF/SF). Am J Pathol. 1998;152(4):855-863.
14. Li H, Alizadeh H, Niederkorn JY. Differential expression of chemokine receptors on uveal melanoma cells and their metastases. Invest Ophthalmol Vis Sci. 2008; 49(2):636-643.
15. Bakalian S, Marshall JC, Logan P, et al. Molecular pathways mediating liver metastasis in patients with uveal melanoma. Clin Cancer Res. 2008;14(4):951-956.
16. All-Ericsson C, Girnita L, Seregard S, Bartolazzi A, Jager MJ, Larsson O. Insulinlike growth factor-1 receptor in uveal melanoma: a predictor for metastatic disease and a potential therapeutic target. Invest Ophthalmol Vis Sci. 2002;43 (1):1-8.
17. Haider HKh, Jiang S, Idris NM, Ashraf M. IGF-1-overexpressing mesenchymal stem cells accelerate bone marrow stem cell mobilization via paracrine activation of SDF-1alpha/CXCR4 signaling to promote myocardial repair. Circ Res. 2008; 103(11):1300-1308.
18. Diaz CE, Rusciano D, Dithmar S, Grossniklaus HE. B16LS9 melanoma cells spread to the liver from the murine ocular posterior compartment (PC). Curr Eye Res. 1999;18(2):125-129.
19. Logan PT, Fernandes BF, Di Cesare S, Marshall JC, Maloney SC, Burnier MN Jr. Single-cell tumor dormancy model of uveal melanoma. Clin Exp Metastasis. 2008; 25(5):509-516.
20. Yang H, Fang G, Huang X, Yu J, Hsieh CL, Grossniklaus HE. In-vivo xenograft murine human uveal melanoma model develops hepatic micrometastases. Melanoma Res. 2008;18(2):95-103.
21. Udagawa T, Fernandez A, Achilles EG, Folkman J, D'Amato RJ. Persistence of microscopic human cancers in mice: alterations in the angiogenic balance accompanies loss of tumor dormancy. FASEB J. 2002;16(11):1361-1370.
22. Yang H, Jager MJ, Grossniklaus HE. Bevacizumab suppression of establishment of micrometastases in experimental ocular melanoma. Invest Ophthalmol Vis Sci. 2010;51(6):2835-2842.
23. Vidal-Vanaclocha F. The prometastatic microenvironment of the liver. Cancer Microenviron. 2008;1(1):113-129.
24. Luzzi KJ, MacDonald IC, Schmidt EE, et al. Multistep nature of metastatic inefficiency: dormancy of solitary cells after successful extravasation and limited survival of early micrometastases. Am J Pathol. 1998;153(3):865-873.
25. Blom DJ, Luyten GP, Mooy C, Kerkvliet S, Zwinderman AH, Jager MJ. Human leukocyte antigen class I expression: marker of poor prognosis in uveal melanoma. Invest Ophthalmol Vis Sci. 1997;38(9):1865-1872.
26. Yang H, Dithmar S, Grossniklaus HE. Interferon alpha 2b decreases hepatic mi-crometastasis in a murine model of ocular melanoma by activation of intrinsic hepatic natural killer cells. Invest Ophthalmol Vis Sci. 2004;45(7):2056-2064.
27. Herwig MC, Grossniklaus HE. Role of macrophages in uveal melanoma. Expert Rev Ophthalmol. 2011;6(4):405-407.
28. Notari L, Miller A, Martínez A, et al. Pigment epithelium-derived factor is a substrate for matrix metalloproteinase type 2 and type 9: implications for down-regulation in hypoxia. Invest Ophthalmol Vis Sci. 2005;46(8):2736-2747.
29. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol. 2000;2(10):737-744.